Protara Therapeutics, Inc. (TARA)
2.33
-0.11
(-4.51%)
USD |
NASDAQ |
Oct 23, 16:00
2.325
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Enterprise Value : -2.080M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -2.080M |
| October 22, 2026 | 4.420M |
| October 21, 2026 | 7.965M |
| October 20, 2026 | 11.51M |
| October 19, 2026 | -2.080M |
| October 16, 2026 | -2.670M |
| October 15, 2026 | 2.056M |
| October 14, 2026 | 6.783M |
| October 13, 2026 | 15.05M |
| October 12, 2026 | 23.92M |
| October 09, 2026 | 23.03M |
| October 08, 2026 | 16.83M |
| October 07, 2026 | 13.28M |
| October 06, 2026 | 11.21M |
| October 05, 2026 | 15.65M |
| October 02, 2026 | 19.78M |
| October 01, 2026 | 23.33M |
| September 30, 2026 | 40.46M |
| September 29, 2026 | 49.91M |
| September 28, 2026 | 52.28M |
| September 25, 2026 | 54.05M |
| September 24, 2026 | 58.19M |
| September 23, 2026 | 69.41M |
| September 22, 2026 | 77.68M |
| September 21, 2026 | 67.64M |
| Date | Value |
|---|---|
| September 18, 2026 | 70.00M |
| September 17, 2026 | 78.87M |
| September 16, 2026 | 74.14M |
| September 15, 2026 | 81.82M |
| September 14, 2026 | 91.27M |
| September 11, 2026 | 85.96M |
| September 10, 2026 | 84.18M |
| September 09, 2026 | 86.55M |
| September 08, 2026 | 90.09M |
| September 04, 2026 | 93.05M |
| September 03, 2026 | 94.82M |
| September 02, 2026 | 93.05M |
| September 01, 2026 | 90.68M |
| August 31, 2026 | 88.32M |
| August 28, 2026 | 85.96M |
| August 27, 2026 | 96.00M |
| August 26, 2026 | 91.27M |
| August 25, 2026 | 94.82M |
| August 24, 2026 | 88.91M |
| August 21, 2026 | 87.73M |
| August 20, 2026 | 90.68M |
| August 19, 2026 | 94.23M |
| August 18, 2026 | 95.41M |
| August 17, 2026 | 95.41M |
| August 14, 2026 | 94.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.047M |
| Brainstorm Cell Therapeutics, Inc. | 10.42M |
| Summit Therapeutics, Inc. | 11.60B |
| Kezar Life Sciences, Inc. | -11.12M |
| Clene, Inc. | 62.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.67M |
| Total Expenses (Quarterly) | 21.67M |
| EPS Diluted (Quarterly) | -0.3552 |
| Earnings Yield | -58.10% |
| Normalized Earnings Yield | -58.10 |